Showing 441-450 of 595 results for "".
Therapeutics Update
https://practicaldermatology.com/topics/psoriasis/therapeutics-update/20530/New products and pharmacologic developmentsCurrents
https://practicaldermatology.com/topics/practice-management/currents/20575/Aesthetic developments herald the dawn of a new age of rejuvenation.Are We All Clear?
https://practicaldermatology.com/topics/psoriasis/are-we-all-clear/20725/Understanding the safety of biologics for psoriasis in real-world settings.New Oral Agent May Shift Psoriasis Treatment Landscape
https://practicaldermatology.com/topics/psoriasis/new-oral-agent-may-shift-psoriasis-treatment-landscape/21258/A notable approval in 2014, apremilast may play an important role in bridging a wide gap in the care of moderate to severe psoriasis.Why Are Dermatologists Not Writing Biologics?
https://practicaldermatology.com/topics/practice-management/why-are-dermatologists-inoti-writing-biologics/23427/Biologics have been shown to be both safe and effective for a variety of indications, so why don’t more dermatologists prescribe them?2024 In Review: This Year's Trends in Dermatology
https://practicaldermatology.com/topics/feature/2024-review-years-trends-dermatology/29886/As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.Fine Particulate Matter and Eczema
https://practicaldermatology.com/issues/july-2025/fine-particulate-matter-and-eczema/36512/The primary objective of this study was to investigate the potential associations between fine particulate matter (specifically PM2.5) exposure and eczema. Researchers on this study set out to explore whether the odds of having eczema would increase with greater PM2.5 exposure, and to identify whethThe State of Private Equity in 2024: Impact on the Practice of Dermatology
https://practicaldermatology.com/columns/practice-management/state-private-equity-2024-impact-practice-dermatology/27173/Physician Growth Partners recently published a white paper, “State of Dermatology Private Equity,” that evaluated market trends, strategies, and more. Practical Dermatology® spoke exclusively with CEO Michael Kroin about how the evolution of private equity is impacting the everyday practitioner andStirring the Pot: Cannabinoids and Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/stirring-the-pot-cannabinoids-and-atopic-dermatitis/20565/Cannabinoids are a diverse group of compounds that may hold significant therapeutic capabilities applicable to many areas of medicine, including dermatology.Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
https://practicaldermatology.com/programs/cme/innovations-in-oncology-learning-center-from-guidelines-to-practice-melanoma/33212/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.